Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
COMMENTARY
Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), raising expectations for a new option in advanced diseases. But unlike conventional drugs that can…
To read the full story
Related Article
- Limited Sites, Bed Capacity Seen as Key Hurdles to Radioligand Therapy Uptake: Urologist
December 8, 2025
- Novartis Eyes Broader Radioligand Therapy Footprint in Japan as Pluvicto Debuts
November 26, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
COMMENTARY
- New Generic Listings Plunge, Industry Heads for a Shakeout
July 1, 2026
- Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze
June 16, 2026
- 20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag
June 9, 2026
- Are Technical Discussions Enough for Japan’s CEA System?
May 25, 2026
- Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises
April 28, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…